Riskpilot← Back to searchSign inGet full accessARCTIC PHARMA AS
ASActiveOrg 998070120.etg, oppgang B 5, 0372 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20121 employees
Revenue 2024
NOK 415K
-92% vs 2023
EBITDA margin
13.5%
+151% vs 2023
Equity ratio
73.2%
Financial strength
Net profit 2024
NOK -2M
+17% vs 2023
| Revenue | NOK 415K | -92% |
| EBITDA | NOK 56K | +151% |
| Net profit | NOK -2M | +17% |
| Total assets | NOK 2,6M | -54% |
| Equity | NOK 1,9M | -45% |
| Employees | 1 | — |
Legal name
ARCTIC PHARMA AS
Org number
998070120
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10. mars 2012
Share capital
NOK 1 092 170
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styreleder og ett styremedlem i fellesskap eller av daglig leder sammen med to styremedlemmer.
Company purpose
Å drive legemiddelutvikling og relaterte konsulenttjenester.
Address
.etg, oppgang B 5, 0372 Oslo
Email
mail@arcticpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 442 | 623 | 2 043 | 3 235 | 5 284 | 5 709 | 3 975 | 353 | 4 663 | 7 287 | 5 483 | 5 291 | 415 |
| Staff expenses | −119 | −409 | −758 | −1 748 | −3 002 | −2 662 | −1 571 | 468 | −1 044 | −119 | −231 | −2 717 | −14 |
| EBITDA | −230 | −24 | 23 | −723 | −897 | −867 | −1 203 | 302 | −831 | −437 | 343 | −110 | 56 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −7 | −7 | −281 | −1 056 | −1 750 | −2 072 | −2 248 | −2 065 |
| EBIT | −230 | −24 | 23 | −723 | −897 | −874 | −1 210 | 21 | −1 886 | −2 187 | −1 730 | −2 358 | −2 009 |
| Net financials | 0 | 1 | −16 | −29 | −25 | −7 | −5 | −13 | −19 | 1 | −17 | −63 | −4 |
| Profit before tax | −229 | −23 | 7 | −752 | −922 | −880 | −1 215 | 9 | −1 905 | −2 185 | −1 747 | −2 421 | −2 014 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −229 | −23 | 7 | −752 | −922 | −880 | −1 215 | 9 | −1 905 | −2 185 | −1 747 | −2 421 | −2 014 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 801 | 881 | 1 821 | 1 987 | 4 281 | 2 877 | 2 230 | 3 559 | 6 488 | 9 240 | 7 395 | 5 576 | 2 554 |
| Equity | 754 | 730 | 947 | 196 | 1 073 | 1 850 | 1 734 | 2 843 | 3 938 | 5 752 | 5 105 | 3 384 | 1 870 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 47 | 150 | 873 | 1 791 | 3 207 | 1 027 | 495 | 224 | 1 786 | 2 486 | 1 410 | 1 561 | 321 |
| Total debt | 47 | 150 | 873 | 1 791 | 3 207 | 1 027 | 495 | 224 | 1 786 | 2 486 | 1 410 | 1 561 | 321 |
EBITDA margin
13.5%
This company
15.8%
Market median
-15% vs market
20122024
Equity ratio
73.2%
This company
38.2%
Market median
+92% vs market
20122024
Return on equity
-107.7%
This company
18.4%
Market median
-685% vs market
20122024
Net profit margin
-485.0%
This company
8.1%
Market median
-6088% vs market
20122024
Asset turnover
0.16×
This company
1.12×
Market median
-86% vs market
20122024
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
20122024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-02-08 – 2012-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Skilling Systemer As | Company | 40.4% | 40.4% | 2022 |
Solan Capital As | Company | 18.3% | 18.3% | 2022 |
| Individual | 5.5% | 5.5% | 2022 | |
| Individual | 4.6% | 4.6% | 2022 | |
| Individual | 3.5% | 3.5% | 2022 | |
Cerolu As | Company | 2.9% | 2.9% | 2022 |
| Individual | 2.8% | 2.8% | 2022 | |
| Individual | 2.4% | 2.4% | 2022 | |
Drug Discovery Laboratory As | Company | 2.4% | 2.4% | 2022 |
| Individual | 1.8% | 1.8% | 2022 | |
Djupdalen As | Company | 1.8% | 1.8% | 2022 |
| Individual | 1.5% | 1.5% | 2022 | |
Acadia Holding As | Company | 1.2% | 1.2% | 2022 |
| Individual | 1.2% | 1.2% | 2022 | |
| Individual | 1.0% | 1.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ARCTIC PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sigurd Ørstavik | Board of Directors | 0 companies |
| Eirik Næss-Ulseth | Chairman | 0 companies |
| Gunnar Hvammen | Board of Directors | 0 companies |